A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia. - Wikidata - wikimedia - TriplyDB

A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia.

A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia.

http://www.wikidata.org/entity/Q36519986

about

Ofatumumab plus chlorambucil as a first-line therapy in less fit patients with chronic lymphocytic leukemia: analysis of COMPLEMENT1 and other monoclonal antibodies association data Idelalisib for the treatment of indolent non-Hodgkin lymphoma: a review of its clinical potential BCR Signaling Inhibitors: an Overview of Toxicities Associated with Ibrutinib and Idelalisib in Patients with Chronic Lymphocytic Leukemia Challenges in the Role of Gammaglobulin Replacement Therapy and Vaccination Strategies for Hematological Malignancy Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axis The Human Kinome Targeted by FDA Approved Multi-Target Drugs and Combination Products: A Comparative Study from the Drug-Target Interaction Network Perspective Targeting PI3K in cancer: impact on tumor cells, their protective stroma, angiogenesis and immunotherapy Management of elderly and unfit patients with chronic lymphocytic leukemia.The shrinking role of chemotherapy in the treatment of chronic lymphocytic leukemia.Richter transformation of CLL.An extensive molecular cytogenetic characterization in high-risk chronic lymphocytic leukemia identifies karyotype aberrations and TP53 disruption as predictors of outcome and chemorefractoriness Idelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity.Chronic lymphocytic leukemia therapy: new targeted therapies on the way Idelalisib for the treatment of non-Hodgkin lymphoma.A Systematic Review and Network Meta-Analysis to Evaluate the Comparative Efficacy of Interventions for Unfit Patients with Chronic Lymphocytic Leukemia.Diagnosis and treatment of chronic lymphocytic leukemia: recommendations from the Brazilian Group of Chronic Lymphocytic Leukemia.PI3Kδ and primary immunodeficiencies.Idelalisib induces PUMA-dependent apoptosis in colon cancer cells.Idelalisib and bendamustine combination is synergistic and increases DNA damage response in chronic lymphocytic leukemia cells.Chronic lymphocytic leukemia (CLL)-Then and now.Small Molecule Inhibitors in Chronic Lymphocytic Lymphoma and B Cell Non-Hodgkin Lymphoma.Targeted therapy in the treatment of chronic lymphocytic leukemia: facts, shortcomings and hopes for the future.The molecular pathogenesis of chronic lymphocytic leukaemia.CD20-targeting in B-cell malignancies: novel prospects for antibodies and combination therapies.Idelalisib and Rituximab Regimen.Idelalisib for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma.Paving the way for new agents; is standard chemotherapy part of the treatment paradigm for chronic lymphocytic leukemia in the future?Translational aspects in targeting the stromal tumour microenvironment: from bench to bedside.Recent advances in therapy of chronic lymphocytic leukaemia.Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.Magic pills: new oral drugs to treat chronic lymphocytic leukemia.The safety profile of monoclonal antibodies for chronic lymphocytic leukemia.Chronic lymphocytic leukemia and small lymphocytic lymphoma: two faces of the same disease.Current Treatment of Chronic Lymphocytic Leukemia.Duvelisib: a phosphoinositide-3 kinase δ/γ inhibitor for chronic lymphocytic leukemia.Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia Outcomes of patients with chronic lymphocytic leukemia treated with first-line idelalisib plus rituximab after cessation of treatment for toxicity.Idelalisib-induced colitis and skin eruption mimicking graft-versus-host disease.PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma.

P2860

Q26738934-40348A33-118E-404C-87CA-906B9F4FD622 Q26747753-0F398E19-B7C3-4A40-8207-62199288859B Q26765624-603A8CB8-263A-45CD-86C5-3ACAB5205178 Q28080304-B96A321D-D517-4F12-87B9-A7960193654A Q28277551-1D7CD4D7-9035-43E9-8F06-64938BC25165 Q28553277-F0B09027-C900-41D7-94AA-DABD57C02F94 Q29248893-B94E14D3-F2EC-4F1A-9643-17894D0689F3 Q30243914-1FCDB355-F42D-46AD-A820-16783CE54091 Q30243968-C4F1C5D9-CFFF-467A-9874-01538B07FAA1 Q30249283-B36BFB03-F569-40B0-9B7C-23620A73A85D Q33709543-09E9501C-A5F1-442B-A679-E5683BB41169 Q37058203-934A54CF-DBD6-4DCB-9548-EE33D6E7E442 Q37097096-18E6910D-B2B5-4FBB-BC0D-CD19BBDBFB85 Q37113544-F88D0679-045D-439B-9DBB-A76C91A3BAD5 Q37114445-26D8930C-8C76-4ECC-B2F4-E03714DCF825 Q37321917-41D89B3D-E1FE-4F93-BA2D-AA1F6D8984FB Q37429218-F649F884-B423-4CAC-8E7A-CAF497E101E0 Q37623828-9101AA26-80F7-453B-8CAA-3BB34F6DFB76 Q37701548-8E637004-01F4-46F0-96CE-35EA81ED1B0B Q37725415-9DB54FC0-8730-4947-9BFF-EA3372F7FAFA Q38675358-BB9665E5-7EB4-4961-874F-110A8CC10B1B Q38691282-6F22DB7C-707F-468C-A131-7791513E0503 Q38738661-B748E10C-FDEF-4D6F-B87E-406A57EA638A Q38748645-A87B46A6-3FF9-49A4-91CA-F5549DFCED0A Q38807514-9E39B26F-6440-40B6-8E77-8B5C0673AB9D Q38821937-B1EB6723-AAC7-4811-9AFB-98FA7C959674 Q38850667-5B8803AB-24F3-45E9-ACFE-914EF97049D7 Q38851368-F4231946-7F1F-4795-A1C3-19F30C2FD650 Q38858806-4016D5F1-B573-4C16-AF98-59A3D336FFD7 Q38862525-A3224796-1DC7-421B-8ABD-590E52143B76 Q38897083-A7B05F2C-D72F-46D4-80B0-9C0B0ECA4A8D Q38943877-5871F15B-6BB1-4B5C-BDD1-8C36E7D1EDD3 Q39018189-C31C6F02-1061-4F86-8D7F-3C43D0047C17 Q39034465-D62E39D4-A379-44D0-9799-5B696AB86CBC Q39129372-469F5714-380D-4180-B1A1-D33B566C7B77 Q39226787-7D4EEE96-A62C-487E-A460-83110DB1E84D Q39227773-35E1B306-A688-4F36-B424-767E1953479E Q39763635-ED6D34D6-8A85-4D2C-9F3F-4D475ECFC663 Q40394474-C9F4E545-5D61-46D6-A1B7-C81BE668E371 Q41994564-FE508AE6-C1B2-4E19-8E18-DD55B0A2D38E

P2860

A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia.

http://www.wikidata.org/entity/Q36519986

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

A phase 2 study of idelalisib ...... chronic lymphocytic leukemia.

@ast

A phase 2 study of idelalisib ...... chronic lymphocytic leukemia.

@en

type

label

A phase 2 study of idelalisib ...... chronic lymphocytic leukemia.

@ast

A phase 2 study of idelalisib ...... chronic lymphocytic leukemia.

@en

prefLabel

A phase 2 study of idelalisib ...... chronic lymphocytic leukemia.

@ast

A phase 2 study of idelalisib ...... chronic lymphocytic leukemia.

@en

P1433

Q36519986-579D6EAC-176C-42A5-AB60-8494288642E3

P1476

Q36519986-5B00D23F-E470-4F48-B8CB-DD86EC6B8AAC

P2093

Q36519986-19E075E1-2F9D-4EA6-B2D3-AF8FBB93EA4C

Q36519986-2276F9C6-74EE-4048-9F00-DBA37A8DCC2D

Q36519986-2469757C-20EF-428E-B9BE-ADFD60164F35

Q36519986-2F67FF06-288D-42F2-803C-7ADBB0CF25E4

Q36519986-3A9DA68F-4742-4B83-A34C-B34058B73DAC

Q36519986-4C0BD715-F77D-4F1C-BAEE-BB34F2EA3344

Q36519986-4E0DE974-0F4A-44AC-A9AB-FDA626F17D14

Q36519986-7EF9D08C-61F1-4030-BF32-7FA3AF4B3D82

Q36519986-83DFA4F2-9474-4940-AD33-287E4AEEE7CC

Q36519986-A455E4BF-341A-4F21-912B-93E724B7D623

P2860

Q36519986-0B938434-DEAA-4115-A843-ABD04D5AAA1D

Q36519986-0B99892D-8CB1-424D-BDB1-7CA5C1AF3881

Q36519986-14466A28-3E59-4E5C-BB43-D968D2CCBFDC

Q36519986-1667604B-6E43-49FD-A196-4689D5B0F83F

Q36519986-20DD5346-A205-47E0-A4D0-B63902702106

Q36519986-2FD464CC-EB7F-4741-9C88-564840CBC007

Q36519986-30089AEE-331E-4C32-A4E0-1D0DAD758C1E

Q36519986-3C8DE7BE-F046-4F69-9E6B-05AC483BFC57

Q36519986-41961E1A-D32B-41B5-8D77-C198D38FE7EB

Q36519986-4A2A0754-E465-430E-B70E-B70F640A66B0

P304

Q36519986-2216A074-E9E5-42D6-9ED2-3333BB8251F8

P31

Q36519986-2A92DECA-5BF6-40D4-B6BF-1FCCDDBAE75C

P356

Q36519986-2116D7CD-610E-4B00-9B59-8A1CA2A29039

P407

Q36519986-E0B3FC12-32E7-4B4E-B44D-3534088349EC

P433

Q36519986-4C6C583E-12EC-4257-B6FC-8D6FAE8AB8B4

P478

Q36519986-698D6BAF-006A-4B09-803F-6098D2889231

P50

Q36519986-8523C677-BFD9-442A-8271-605388568C88

P577

Q36519986-DEA8C8C2-80D8-45AE-ACCA-5AEFF9F08EDD

P5875

Q36519986-639DFF4C-7135-40C4-80FA-30AF1093FE60

P698

Q36519986-CF842DF8-807F-4C31-AE7E-BE113D8E2A8A

P921

Q36519986-211B26FC-B401-4C8C-A179-0E7085B4521C

Q36519986-7A1E6BB8-CBC6-4F5A-BB6D-E60F4AE282F0

P932

Q36519986-2FC408DD-058F-40AB-9B84-980E5B2556AA

P356

BLOOD-2015-03-630947

P1433

P1476

A phase 2 study of idelalisib ...... chronic lymphocytic leukemia.

@en

P2093

Albert S Yu

http://www.w3.org/2001/XMLSchema#string

Andrew D Zelenetz

http://www.w3.org/2001/XMLSchema#string

David M Johnson

http://www.w3.org/2001/XMLSchema#string

Ian Flinn

http://www.w3.org/2001/XMLSchema#string

Jan A Burger

http://www.w3.org/2001/XMLSchema#string

Langdon L Miller

http://www.w3.org/2001/XMLSchema#string

Leanne Holes

http://www.w3.org/2001/XMLSchema#string

Nicole Lamanna

http://www.w3.org/2001/XMLSchema#string

Roger D Dansey

http://www.w3.org/2001/XMLSchema#string

Ronald L Dubowy

http://www.w3.org/2001/XMLSchema#string

P2860

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

Molecular pathways: targeting phosphoinositide 3-kinase p110-delta in chronic lymphocytic leukemia

TP53 mutation and survival in chronic lymphocytic leukemia.

Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial.

PI3K in lymphocyte development, differentiation and activation

Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia

The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism

Cancer treatment and survivorship statistics, 2014

Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.

P304

2686-2694

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2015-03-630947

http://www.w3.org/2001/XMLSchema#string

P407

P433

25

http://www.w3.org/2001/XMLSchema#string

P478

126

http://www.w3.org/2001/XMLSchema#string

P50

Michael J. Keating

P577

2015-10-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

282911541

http://www.w3.org/2001/XMLSchema#string

P698

26472751

http://www.w3.org/2001/XMLSchema#string

P921

P932

4732760

http://www.w3.org/2001/XMLSchema#string